Ripple Therapeutics enters collaboration with Bausch + Lomb

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Ripple Therapeutics, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, recently announced that, earlier this year, it entered into an evaluation program and licensing option agreement with an affiliate of Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better.

Ripple Therapeutics is an OBIO® member, an alumnus of our BDSP™, CAAP® and WiHI programs, and presented at the OBIO® Investment Summit.

Read more
Arsheen Kaur
Previous

Vasomune Therapeutics and AnGes expand the scope of the co-development agreement to target additional indications
Next

Kixcare partners with Manulife to provide 24x7 virtual care for children across Canada